PharmaShots | Incisive News in 3 Shots

Subscribe Now

All Posts by Date

PharmaShots Weekly Snapshots (February 28- March 04, 2022)

PharmaShots Weekly Snapshots (February 28- March 04, 2022)

March 4, 2022

Fulcrum Seeks to Initiate the P-III (REACH) Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy

Fulcrum Seeks to Initiate the P-III (REACH) Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy

March 4, 2022

Aravive Reports Updated Results of Batiraxcept in the P-Ib Study for the Treatment of Clear Cell Renal Cell Carcinoma

Aravive Reports Updated Results of Batiraxcept in the P-Ib Study for the Treatment of Clear Cell Renal Cell Carcinoma

March 4, 2022

Amgen’s Lumykras (sotorasib) Receives NICE Recommendation for the Treatment of Non-Small-Cell Lung Cancer

Amgen’s Lumykras (sotorasib) Receives NICE Recommendation for the Treatment of Non-Small-Cell Lung Cancer

March 4, 2022

AstraZeneca and Sanofi Publishes Results of Nirsevimab in P-III (MELODY) Trial for the Treatment of RSV in the NEJM

AstraZeneca and Sanofi Publishes Results of Nirsevimab in P-III (MELODY) Trial for the Treatment of RSV in the NEJM

March 4, 2022

BeiGene’s Brukinsa (zanubrutinib) Receives the Health Canada Approval for the Treatment of Marginal Zone Lymphoma

BeiGene’s Brukinsa (zanubrutinib) Receives the Health Canada Approval for the Treatment of Marginal Zone Lymphoma

March 4, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us